Oncology company BeOne Medicines Ltd (NASDAQ:ONC) (HKEX:06160) (SSE:688235) announced on Thursday that the European Commission has approved TEVIMBRA (tislelizumab) in combination with gemcitabine and cisplatin as a first-line treatment for adults with metastatic or recurrent nasopharyngeal carcinoma not amenable to curative surgery or radiotherapy.
The approval is based on data from the Phase 3 RATIONALE-309 trial, which demonstrated a statistically significant improvement in progression-free survival. Patients receiving TEVIMBRA plus chemotherapy saw a 48% reduction in the risk of disease progression or death, with median progression-free survival of 9.2 months versus 7.4 months in the placebo arm.
An updated analysis showed consistent efficacy and a sustained overall survival benefit, with median overall survival reaching 45.3 months for the TEVIMBRA group compared to 31.8 months for placebo.
TEVIMBRA plus chemotherapy was generally well tolerated, and no new safety signals emerged. The most common Grade 3 or 4 adverse reactions were neutropenia, anaemia, and thrombocytopenia.
This marks the second European Union approval for TEVIMBRA in 2025, expanding its existing indications across gastric, oesophageal, small cell lung, and non-small cell lung cancers.
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001